|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
ELV056621663 |
003 |
DE-627 |
005 |
20230624233221.0 |
007 |
cr uuu---uuuuu |
008 |
220205s2022 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.earlhumdev.2022.105538
|2 doi
|
028 |
5 |
2 |
|a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001656.pica
|
035 |
|
|
|a (DE-627)ELV056621663
|
035 |
|
|
|a (ELSEVIER)S0378-3782(22)00001-9
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
082 |
0 |
4 |
|a 610
|q VZ
|
082 |
0 |
4 |
|a 610
|q VZ
|
084 |
|
|
|a 44.45
|2 bkl
|
100 |
1 |
|
|a Guedalia, Joshua
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Primary risk stratification for neonatal jaundice among term neonates using machine learning algorithm
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
520 |
|
|
|a Neonatal jaundice occurs in approximately 60% of term newborns. Although risk factors for neonatal jaundice have been studied, all the suggested strategies are based on various newborn tests for bilirubin levels. We aim to stratify neonates into risk groups for clinically significant neonatal jaundice using a combined data analysis approach, without serum bilirubin evaluation.
|
700 |
1 |
|
|a Farkash, Rivka
|4 oth
|
700 |
1 |
|
|a Wasserteil, Netanel
|4 oth
|
700 |
1 |
|
|a Kasirer, Yair
|4 oth
|
700 |
1 |
|
|a Rottenstreich, Misgav
|4 oth
|
700 |
1 |
|
|a Unger, Ron
|4 oth
|
700 |
1 |
|
|a Grisaru Granovsky, Sorina
|4 oth
|
773 |
0 |
8 |
|i Enthalten in
|n Elsevier Science
|a Abdel-Aziz, Tarek Ezzat ELSEVIER
|t Study of serum leptin in well differentiated thyroid carcinoma: Correlation with patient and tumor characteristics
|d 2014
|g Amsterdam [u.a.]
|w (DE-627)ELV022803173
|
773 |
1 |
8 |
|g volume:165
|g year:2022
|g pages:0
|
856 |
4 |
0 |
|u https://doi.org/10.1016/j.earlhumdev.2022.105538
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_U
|
912 |
|
|
|a GBV_ELV
|
912 |
|
|
|a SYSFLAG_U
|
912 |
|
|
|a SSG-OLC-PHA
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_350
|
936 |
b |
k |
|a 44.45
|j Immunologie
|q VZ
|
951 |
|
|
|a AR
|
952 |
|
|
|d 165
|j 2022
|h 0
|